Assessing drug development risk using big data and machine learning
AffiliationIntelligencia Inc., New York, New York.
MetadataShow full item record
AbstractIdentifying new drug targets and developing safe and effective drugs is both challenging and risky. Furthermore, characterizing drug development risk, the probability that a drug will eventually receive regulatory approval, has been notoriously hard given the complexities of drug biology and clinical trials. This inherent risk is often misunderstood and mischaracterized, leading to inefficient allocation of resources and, as a result, an overall reduction in R&D productivity. Here we argue that the recent resurgence of Machine Learning in combination with the availability of data can provide a more accurate and unbiased estimate of drug development risk.
CitationVergetis V, Skaltsas D, Gorgoulis VG, Tsirigos A. Assessing Drug Development Risk Using Big Data and Machine Learning. Cancer Res. 2021;81(4):816-9.
- Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?
- Authors: Ménard T, Koneswarakantha B, Rolo D, Barmaz Y, Popko L, Bowling R
- Issue date: 2020 Mar
- An Overview of Machine Learning and Big Data for Drug Toxicity Evaluation.
- Authors: Vo AH, Van Vleet TR, Gupta RR, Liguori MJ, Rao MS
- Issue date: 2020 Jan 21
- Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.
- Authors: Nakayama H, Matsumaru N, Tsukamoto K
- Issue date: 2019 Feb
- Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
- Authors: Mendes D, Rigueiro G, Silva RS, Penedones A, Alves C, Sousa G, Batel-Marques F
- Issue date: 2020 Jan
- PTML Model for Selection of Nanoparticles, Anticancer Drugs, and Vitamins in the Design of Drug-Vitamin Nanoparticle Release Systems for Cancer Cotherapy.
- Authors: Santana R, Zuluaga R, Gañán P, Arrasate S, Onieva E, Montemore MM, González-Díaz H
- Issue date: 2020 Jul 6